Gainers

• BioLine Rx (NASDAQ:BLRX) stock increased by 12.5% to $3.11 during Monday's after-market session. The company's market cap stands at $12.9 million.
• CDT Equity (NASDAQ:CDT) shares rose 9.35% to $1.64. The market value of their outstanding shares is at $8.3 million.
• NuCana (NASDAQ:NCNA) stock increased by 7.88% to $2.19. The company's market cap stands at $9.0 million. As per the news, the Q1 earnings report came out 2 days ago.
• PharmaCyte Biotech (NASDAQ:PMCB) stock moved upwards by 7.49% to $0.82. The market value of their outstanding shares is at $8.6 million.
• CapsoVision (NASDAQ:CV) stock increased by 6.91% to $6.8. The company's market cap stands at $322.5 million. The company's, Q1 earnings came out 2 days ago.
• Polaryx Therapeutics (NASDAQ:PLYX) stock rose 6.52% to $2.94. The company's market cap stands at $126.4 million.

Losers

• AIM ImmunoTech (AMEX:AIM) stock fell 16.8% to $0.34 during Monday's after-market session. The company's market cap stands at $3.9 million. The company's, Q1 earnings came out yesterday.
• Picard Medical (AMEX:PMI) stock fell 14.37% to $0.15. The company's market cap stands at $14.7 million. As per the press release, Q1 earnings came out yesterday.
• WORK Medical Tech Gr (NASDAQ:WOK) stock fell 10.53% to $0.34.
• Virax Biolabs Group (NASDAQ:VRAX) stock decreased by 9.79% to $0.21. The market value of their outstanding shares is at $1.1 million.
• Sunshine Biopharma (NASDAQ:SBFM) shares fell 9.42% to $0.46. The company's market cap stands at $1.3 million. As per the news, the Q1 earnings report came out 3 days ago.
• Atlantic International (NASDAQ:ATLN) stock decreased by 8.4% to $1.31. The company's market cap stands at $112.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.